Related by context. All words. (Click for frequent words.) 67 Lantibio 64 Soliris TM eculizumab 63 Generx TM 62 EP #R 61 Adenuric R 61 immatics 61 molecular imaging radiopharmaceutical 61 Personalized Immunotherapy 61 Alzhemed TM 61 Onalta ™ 61 pafuramidine maleate 61 Virulizin R 61 PANVAC VF 61 Proxinium TM 60 Iluvien ® 60 hoFH 60 IMA# 60 RhuDex ® 60 pivotal bioequivalence 60 PHX# 60 GTC recombinant human 60 acyclovir Lauriad R 60 OvaRex ® MAb 60 Rhucin ® recombinant 60 kidney urologic 60 SNT MC# 60 budesonide MMX Phase III 60 volociximab 60 Allovectin 7 R 59 Xcytrin R 59 Lixivaptan 59 TheraCIM 59 acetonide FA 59 FOLOTYN ® 59 novel therapeutic antibodies 59 alvespimycin 59 Zenvia ™ 59 Alinia 59 targeted radiotherapeutic 59 phase IIb clinical 59 ALN RSV# 59 Elafin 59 Prodarsan R 59 SEPET TM 59 Civacir 59 blood clot dissolver 59 #D#C# 59 CEQ# 59 registrational 59 Phase IIb clinical trials 59 unoprostone isopropyl 59 fosbretabulin 59 Panzem R 59 inhaled AAT 58 UPLYSO 58 ospemifene 58 deforolimus 58 injectable collagenase 58 PNP inhibitor 58 PrevOnco 58 Evoltra ® 58 EnzymeRx 58 Kamada AAT 58 M Vax 58 Surfaxin LS 58 valtorcitabine 58 Uvidem 58 KRYSTEXXA TM pegloticase 58 BLA filing 58 Oncoscience AG 58 human C1 inhibitor 58 octreotide implant 58 Angiocept 58 OvaRex R 58 StemEx R 58 PDX pralatrexate 58 IR BioSciences Holdings 58 hereditary deficiency 58 Fibrillex TM 58 phase IIa clinical 58 IMiDs ® compound 58 DEEP AF 58 Vascular Wrap TM 58 humanised monoclonal antibody 58 delivers fluocinolone acetonide FA 58 oral picoplatin 58 ELACYT 58 Gentamicin Surgical Implant 58 Biopartners 58 Dyloject TM 58 Augment Injectable 58 Modrenal R 58 HepeX B 58 YONDELIS R 58 TRO# 57 orally administered inhibitor 57 forodesine 57 PDE4 inhibitor 57 Ophena 57 Aviptadil 57 Phase IIb III 57 Etubics 57 successfully commercialize Iluvien 57 Falk Pharma 57 Panzem R NCD 57 factor VIIa 57 visit www.dobimedical.com 57 KNS # 57 virus HCV protease inhibitor 57 Tyzeka Sebivo 57 Cellegesic 57 theranostic 57 oral ridaforolimus 57 thalidomide Thalomid 57 EDEMA3 57 rALLy clinical trial 57 ATryn ® 57 Peginterferon alfa 2b 57 Cloretazine 57 TOPICA 57 Cloretazine ® 57 Phase lll 57 synthetic retinoid 57 Lovaxin C 57 GTC recombinant form 57 Phase #b/#a clinical 57 Cx# [002] 57 Bendamustine 57 TACI Ig 57 Factor VIIa 57 JOULFERON 57 Rhucin ® 57 pentostatin 57 Somatuline R Autogel R 57 Cardium Therapeutics TM 57 refractory chronic lymphocytic 57 trastuzumab DM1 T DM1 57 Solazed ™ 57 BrachySil TM 57 Phase III multicenter 57 GATTEX ® 57 Phase Ib study 57 IND enabling 57 Neo Urinary Conduit 57 Combidex 56 RELISTOR ® 56 ATryn R 56 GEM OS2 56 LEUKINE 56 talactoferrin 56 tiapamil 56 LUVENIQ 56 Cethrin 56 ADP receptor antagonist 56 Chemophase 56 Ampligen r 56 RhuDex TM 56 YONDELIS 56 radiation sensitizer 56 ATL# [002] 56 bardoxolone 56 methylnaltrexone bromide 56 Fludara ® 56 immunotherapeutic vaccine 56 catheter occlusion 56 Veronate 56 ONCASPAR 56 vosaroxin 56 SOLTAMOX TM tamoxifen citrate 56 Phase #b/#a 56 Loramyc 56 GED aPC 56 Ketotransdel 56 Posiphen TM 56 ADVEXIN p# therapy 56 Onalta 56 candidate deforolimus 56 pain palliation 56 OMNARIS HFA 56 JZP 56 Phase 2a clinical trials 56 Bioral Amphotericin B 56 drug ISA# 56 oncolytic vaccine 56 Arno Therapeutics 56 ZALBIN 56 BCR ABL inhibitor 56 Kuvan R 56 PI3K/Akt pathway inhibitor 56 Application MAA 56 histone deacetylase inhibitor 56 AA amyloidosis 56 Triapine 56 Genasense ® 56 ART# 56 Evoltra TM 56 Thelin tm 56 acyclovir Lauriad ® 56 SinuNase TM 56 EGRIFTA TM 56 confirmatory Phase III 56 docetaxel Taxotere ® 56 ENRICH trial 56 Oracea TM 56 Junovan TM 56 Martin Nicklasson CEO 56 Proellex TM 56 ularitide 56 lintuzumab SGN 56 Creabilis Therapeutics 56 IIa trial 56 BioNumerik 56 EGRIFTA ™ 56 including eniluracil ADH 56 multicenter clinical trials 56 CoAxia 56 Collategene 56 DURIN TM 56 multicenter Phase II 56 XL# anticancer compounds 56 MOZOBIL 56 Urocidin TM 56 Marketing Authorization Application 56 EchoCRT 56 Æterna Zentaris 56 PrevOnco ™ 56 PDE# inhibitors 55 BioSET 55 Cetrorelix 55 Maxy G# 55 HuMax CD4 55 polysaccharide polymer 55 Dalbavancin 55 Phase IIIb study 55 Vascugel 55 oral salmon calcitonin 55 Lucanix R 55 TLK# 55 Anturol TM 55 ACCLAIM II 55 SYCREST 55 telomerase therapeutic 55 Aplidin 55 Omigard 55 novel oral anticoagulant 55 MAA submission 55 CYT# potent vascular disrupting 55 Allovectin 7 r 55 treat chronic sinusitis 55 Sebivo 55 eprodisate KIACTA TM 55 Symadex 55 LHRH antagonist 55 Nanobody R 55 Phase IIIb clinical 55 MAGE A3 ASCI 55 Unit Dose Budesonide 55 CoFactor 55 AzaSite Xtra 55 Jerini Ophthalmic 55 DIFICID ™ 55 Charlesson 55 Multiferon R 55 CancerVax Corporation 55 Aganocide 55 Emezine 55 Phase 1b clinical trials 55 EDEMA3 trial 55 AMITIZA lubiprostone 55 Clolar ® 55 TheraCIM h R3 55 IND submission 55 LUMINATE 55 Liprotamase 55 OMAPRO ™ 55 ELIQUIS 55 reslizumab 55 PGL# 55 GnRH antagonist 55 HuMax TAC 55 commercialize AzaSite 55 PFO migraine 55 Pradefovir 55 Hematide ™ 55 EOquin 55 diarrhea predominant irritable 55 Centralized Procedure 55 Pivotal Phase III 55 lenalidomide Revlimid R 55 huC# DM4 55 Homspera TM 55 cutaneous T 55 StaphVAX R 55 GATTEX ™ 55 Adnectin 55 BENLYSTA ® 55 Marketing Authorisation Application 55 tramiprosate Alzhemed TM 55 topically applied SEPA 55 TOCOSOL Paclitaxel 55 cinacalcet HCl 55 Spiegelmer ® 55 rxRNA 55 Eluting Stent 55 UltiMAb 55 ganetespib 55 humanized anti 55 Prodarsan 55 CINOD 55 Cloretazine R VNP#M 55 Plicera 55 hyaluronidase enzyme 55 recurrent metastatic 55 candidate epratuzumab 55 Initiates Phase II 55 RECOTHROM R 55 product platforms AZX# 55 cUTI 55 Allovectin 7 ® 55 Plasmin 55 MEPACT 55 TRX1 55 MOVIPREP R 55 CR# vcMMAE 55 TroVax ® 55 Nitec 55 Sanvar R 55 ATL# [001] 55 KRN# 55 collagenase clostridium histolyticum 55 LibiGel ® 54 severe hypercholesterolemia 54 ThermoDox ® clinical 54 PRECISE trial 54 Luveniq 54 intravesical infusion therapy 54 Bezielle 54 IL# PE#QQR 54 Combo Stent 54 Aryplase 54 COMFORT II 54 Pivotal Trial 54 EOquin TM 54 Selective Electrochemical Tumor Ablation 54 Facet Solutions 54 relapsed refractory multiple myeloma 54 ORTHOCON 54 Impavido R 54 Nabi HB Intravenous 54 intravenous AAT 54 Initiates Enrollment 54 generation rotary VAD 54 Phase 1a clinical 54 BLA submission 54 Amigal 54 RECOTHROM ® 54 Kosan dependence 54 evaluating satraplatin 54 glucokinase activator 54 investigational humanized monoclonal antibody 54 Sigma Tau SpA 54 Cerashield TM 54 Liprostin 54 ASONEP 54 XIAPEX ® 54 anti CD3 monoclonal 54 ongoing Phase IIIb 54 BCX# 54 Potelligent Technology 54 oral calcitonin 54 Davanat 54 ComfortScan system 54 DAVANAT ® 54 LymphoStat B TM 54 Loramyc TM 54 thymalfasin 54 HCV protease inhibitor 54 Omigard TM 54 vidofludimus 54 acne impetigo 54 TELINTRA R 54 PEG PAL 54 CA4P 54 Ergomed 54 OncoGel 54 Icatibant 54 ThermoDox R 54 Lung Rx 54 registrational trial 54 N acetylgalactosamine 6 54 ADVANCE PD 54 Fabry Disease 54 PLK1 SNALP 54 EVIZON TM 54 Troxatyl 54 sNDA submission 54 ZFP Therapeutics 54 compound INCB# 54 NeuroFlo 54 BRILINTA 54 antisense inhibitors 54 CBLC# 54 Sonatherm 54 Veregen TM 54 novel histone deacetylase 54 Hepatocellular Carcinoma HCC 54 ONCONASE 54 RPL# 54 dextofisopam 54 MelaFind R 54 Noscira 54 INCB# [001] 54 AMPK activators 54 Syntonix 54 RHUCIN 54 CIMAB SA 54 Onrigin 54 receptor tyrosine kinase inhibitor 54 Urocortin 2 54 miRNA therapeutics 54 EVICEL 54 Entereg R 54 TELCYTA 54 placebo controlled Phase III 54 chimeric monoclonal antibody 54 Simulect 54 Glybera R 54 Multimeric 54 bevacizumab Avastin ® 54 JAK2 Inhibitor 54 Phase #/#a 54 Onconase 54 systemic RNAi 54 Resten NG 54 IAP inhibitor 54 Cabrellis 54 ZYBRESTAT fosbretabulin 54 Phase Ib II 54 LEVADEX ™ 54 IV APAP 54 IMC #F# 54 multicenter Phase III 54 preclinical efficacy 54 DEB# 54 Tectin TM 54 acadesine 54 Xanafide 54 ImQuest 54 mitogen activated ERK kinase 54 Squalamine 54 CCX# 54 dihydrochloride Tablets 54 AmpliMed 54 Epitomics 54 RIGScan CR 54 Allovectin 7 54 ISTODAX 54 EndoTAG TM 54 recurrent malignant glioma 54 toenail onychomycosis 54 Aflibercept 54 selective androgen receptor modulator 54 Litx 54 lorvotuzumab mertansine 54 Carticept 54 Alvesco R 54 Urocidin 54 trastuzumab Herceptin R 54 Veregen R 54 Nexavar sorafenib 54 dextromethorphan quinidine 54 antibody MAb 54 Mipomersen 54 Curaxin CBLC# 53 EndoTAG TM -1 53 Orphan Drug status 53 Phenoptin 53 Vicinium TM 53 Digna Biotech 53 Dacogen injection 53 topical anti infective 53 Neuradiab 53 mGluR5 negative 53 Thrombin topical Recombinant 53 IMC #B 53 ARRY # 53 generation purine nucleoside 53 MKC# MKC# PP 53 Neovasc Reducer 53 sorafenib tablets 53 Endotis 53 PREOS R 53 Immunotherapeutic 53 Tibotec BVBA 53 Biologic License Application BLA 53 Eniluracil 53 Bone Graft 53 Phase Ib IIa 53 BioAxone 53 lucinactant 53 Velcade bortezomib 53 Abiraterone acetate 53 Luteinizing Hormone Releasing Hormone 53 Spirogen 53 Imprime PGG 53 small molecule thrombopoietin 53 SYN# 53 XIAFLEX ® 53 SPL# Gel vaginal microbicide 53 Sirion Therapeutics 53 HCD# [002] 53 methylnaltrexone 53 BLP# Liposome Vaccine 53 TORISEL 53 systemic anaplastic large 53 SUCCEED trial 53 FavId 53 phase IIb trial 53 Initiates Phase III 53 clevudine 53 RAV# 53 TRANSDUR Sufentanil 53 BAY #-# 53 REPEL CV 53 Amigal TM 53 dalbavancin 53 BrachySil ™ 53 romidepsin 53 Fresenius Biotech 53 Ganite ® 53 Hsp# Inhibitor 53 somatostatin analogue 53 Catena ® 53 cMET inhibitor 53 DPP4 inhibitor 53 Neulasta R 53 AERx iDMS 53 Crofelemer budesonide foam 53 Myoblast Program 53 AzaSite Plus 53 ZEFTERA TM Zevtera TM 53 Fibrin Pad 53 ATL/TV# 53 ZYBRESTAT TM 53 induced macular edema 53 Acute Radiation Syndrome ARS 53 pralatrexate 53 subconjunctival injection 53 dose escalation clinical 53 Nautilus Biotech 53 tosedostat 53 GRN# 53 SUTENT ® 53 personalized cellular immunotherapy 53 Phase 2b Clinical Trial 53 IgG1 monoclonal antibody 53 Capesaris 53 HDACi 53 commercialize deforolimus 53 anticancer compound 53 fallopian tube cancers 53 radiotherapeutic 53 M Enoxaparin 53 Kit CD# positive 53 TAXUS Element Paclitaxel Eluting 53 Mersana 53 OZURDEX ® 53 PROVENGE ® 53 vernakalant hydrochloride 53 Methylnaltrexone 53 Phase III HEAT 53 Harry Palmin President 53 novel emulsion formulation 53 recurrent metastatic ovarian cancer 53 NurOwn 53 rALLy trial 53 novel immunotherapeutic 53 PregLem 53 Azedra 53 RenaZorb TM 53 Behcet uveitis 53 ADAGIO study 53 DiabeCell ® 53 LymphoStat B belimumab 53 liposomal formulation 53 elotuzumab 53 TLR9 agonist 53 EFAPROXYN 53 Phase III pivotal 53 ridaforolimus 53 Yondelis ® 53 Teysuno 53 MD FACS FAAP 53 TG# [001] 53 teduglutide 53 Marketing Authorization Application MAA 53 Medidur TM FA 53 mSEPT9 biomarker 53 ELADUR ™ 53 ProMune 53 Phase 1b trial 53 Kahalalide F 53 Fodosine 53 recurrent glioblastoma multiforme 53 CRMD# 53 vapreotide acetate 53 HuMax EGFr 53 selective immunoproteasome inhibitor 53 ZFNs clinical trials 53 Raptiva ® 53 Prestara 53 subcutaneous immunoglobulin 53 adenosine A2A 53 Celladon Corporation 53 Orphan Drug designations 53 dirucotide 53 liposomal delivery 53 CureVac 53 systemic immunosuppressive drugs 53 vemurafenib 53 investigational pan BCR 53 Diabetic Macular Edema 53 visit http:/www.clinicaltrials.gov/ 53 lomitapide 53 leading oral taxane 53 pharmacokinetic PK study 53 Nanobody 53 DNA methylation biomarkers 53 Kepivance 53 AcryMed Incorporated 53 APEX PD 53 Orphan Status 53 MYDICAR ® 53 IV Busulfex 53 Teplizumab 53 Archexin 53 Receives Orphan Drug Designation 53 SinuNase ™ 53 velaglucerase alfa 52 PRECISE Trial 52 BRIM2 52 Presents Preclinical 52 Therinject 52 peginesatide 52 Aplidin R 52 Besivance 52 IAP inhibitors 52 Phase 2a trial 52 Alfa Wassermann 52 cleavable linker 52 metastatic HRPC 52 somatostatin analog 52 HepeX B TM 52 TRANSDUR ™ 52 REG1 Anticoagulation System 52 TaiGen 52 TRB Chemedica 52 eligen 52 PharmaMar 52 MIST II 52 phase IIa 52 Bexion 52 KYTHERA 52 Preotact R 52 5 HT2C 52 RELOVAIR ™ 52 Vascular Disrupting Agent 52 selective A2A adenosine receptor 52 humanized monoclonal 52 ProFibrix 52 R bendamustine hydrochloride 52 XYOTAX TM 52 Anavex #-# 52 AFRS TM 52 Hexvix ® 52 Locteron ® 52 Certican 52 ABRAXANE TM 52 amrubicin 52 valopicitabine NM# 52 molecular chaperone regulation 52 Rhein Biotech GmbH 52 canakinumab 52 Clevudine 52 OLpur TM H2H 52 developing Zerenex ferric 52 Granted Orphan Drug 52 pseudobulbar affect PBA 52 paclitaxel poliglumex 52 CCX# B 52 Leukine ® 52 PROPEL trial 52 Medidur FA 52 Kuvan TM sapropterin 52 Genasense R oblimersen 52 RhuDex R 52 Recombinant Human 52 Phase IIa trials 52 metastatic sarcomas 52 dose escalation Phase 52 Ophthotech 52 Oasmia 52 Friedreich Ataxia FRDA 52 recombinant biopharmaceutical 52 ProEthic Pharmaceuticals 52 nasal calcitonin product 52 oxymorphone ER 52 NEBIDO 52 Rapinyl 52 RHEI Pharmaceuticals 52 JAK inhibitors 52 Bioral ® 52 Resten MP 52 Meets Primary Endpoint 52 InterfeRx 52 Galderma SA 52 Begins Dosing 52 Inhaled AAT 52 Wellstat 52 Juvantia 52 PRIMO CABG 52 ProBioGen 52 PEGINTRON TM 52 PIX# trial 52 label Lipofen R 52 Inclinix 52 Aurexis 52 Vernakalant 52 GTC NASDAQ GTCB 52 myoblast therapy 52 Novosom 52 Solesta 52 Initiates Clinical 52 tanespimycin 52 Phase 2a clinical 52 CINTREDEKIN BESUDOTOX 52 modified glutathione analog 52 Bicifadine 52 drug eluting stent DES 52 AQ4N 52 Sigma Tau Pharmaceuticals 52 immunomodulatory therapy 52 highly purified pasteurized 52 GALNS 52 budesonide foam 52 bilastine 52 Bio3 Research 52 Phase IIa trial 52 Tykerb lapatinib 52 Phase Ib clinical 52 fenretinide 52 fluoropyrimidine 52 INSPIRE Trial Phase III 52 liver resection surgeries 52 novel peptides 52 Phase IIb trials 52 relapsed multiple myeloma 52 Ilaris ® 52 Vaccinex 52 LB# [003] 52 Proquin XR 52 Phase III confirmatory 52 Phase 2b kidney transplant 52 aerosolized AAT 52 DIABECELL 52 Phase III Clinical Trial 52 evaluating REVLIMID 52 ongoing Phase 1b 52 RANK Ligand inhibitor 52 Preotact 52 fusion enhancers 52 cartilage regeneration 52 OMP #M# 52 Ceragenin ™ 52 POSIDUR TM 52 IMiDs ® 52 please visit www.advaxis.com 52 Cerashield ™ 52 antibacterial therapeutics 52 clinicaltrials 52 Anthim 52 Anticalin R 52 Novartis NVS Snapshot Report 52 Sanochemia 52 Hedgehog Pathway Inhibitor 52 IoGen 52 Belimumab 52 GPR# agonist 52 MAb therapy 52 hepatitis C HCV 52 NV Organon 52 Astellas Deutschland GmbH 52 Aganocide ® 52 Investigational Device Exemption IDE 52 Zirgan 52 Nycomed GmbH 52 Reports Preclinical Data 52 Taiho Pharmaceutical 52 Vascular Wrap 52 CIMYM 52 Canvaxin 52 Septin9 biomarker 52 rThrombin 52 PROVENGE sipuleucel T 52 topical ophthalmic 52 MGCD# [001] 52 Nexavar ® 52 Tolerx 52 PTH analogue 52 Callisto initiated 52 Galenea 52 HCV protease inhibitors 52 Fovea Pharmaceuticals 52 polymer platinate 52 Spheramine 52 MEK Inhibitor 52 Acetavance TM 52 Solasia 51 Sanquin 51 aurora kinase 51 CALGB # [002] 51 dirucotide MBP# 51 Sankyo Pharma 51 lorcaserin Phase 51 Gruppo Angelini 51 Orphan Drug Status 51 antitumoral 51 randomized Phase IIb 51 RenalGuard System TM 51 Phase III clinical 51 HepaGam B 51 ExCell study 51 Quark Pharmaceuticals 51 relapsing remitting MS RRMS 51 Myolimus 51 FluoroPharma 51 XIENCE V Everolimus Eluting 51 anti inflammatory NSAID 51 HSP# inhibitor 51 CureTech 51 Argatroban 51 PDL# 51 ReN# 51 fipamezole 51 Phase III clinical trials 51 stated Michelle Berrey 51 Sapacitabine 51 Bayer HealthCare Onyx Pharmaceuticals 51 ProLindac TM 51 evaluating tivozanib 51 CRACM 51 MyoCell 51 IV melanoma 51 Enzo Therapeutics 51 Phase Ib clinical trials 51 Lantibio Inc. 51 Phase #/#a trial 51 refractory metastatic colorectal cancer 51 Eligard ® 51 commercialize Aganocides 51 apaziquone 51 Phase III Pivotal 51 cathepsin K inhibitor 51 MicroDose 51 dacetuzumab SGN 51 NeoDisc 51 Bellicum 51 alvimopan 51 StemEx 51 TRANSDUR ® 51 candidate Zenvia 51 compound KOS 51 Severe VOD 51 pralatrexate injection folate analogue 51 transfemoral 51 HemoGenix 51 NEUMUNE 51 Phase Ib 51 Therapeutic Vaccine 51 Cancidas 51 PROCHYMAL 51 Edwards SAPIEN valve 51 Campath ® 51 Tetrabenazine 51 neurology immunology 51 Cenomed 51 Entereg TM 51 VITAL Trial 51 Sym# 51 Genasense ® oblimersen 51 Cell Pouch System 51 Virulizin 51 direct renin inhibition 51 Angiox R 51 SILENOR TM 51 BioSTAR R 51 recurrent NSCLC 51 prostone 51 Pharmion Corporation 51 GammaCan 51 GAMMAGARD 51 cortical stimulation 51 oxypurinol 51 SynCon 51 Convivia TM 51 Cardiac Cryoablation System 51 lanreotide 51 dermatological indications 51 PEGylated interferon 51 Raptiva R 51 Tarsa Therapeutics 51 BioRexis 51 TÎ ² 4 51 initiate Phase 1b 51 Phase 2b clinical 51 Increlex R 51 therapeutic monoclonal antibodies 51 Panzem ® 51 ZYBRESTAT 51 Cascade LifeSciences 51 Tavocept 51 STEDESA 51 initiated Phase 1b 51 sodium glucose transporter 51 Virium 51 registrational Phase 51 Tramiprosate ALZHEMED TM 51 Phenomix Corporation 51 Dacogen decitabine 51 Genasense oblimersen sodium Injection 51 Phase 2b trial 51 GATTEX TM 51 DAVANAT R 51 mondoBIOTECH 51 TFChem 51 Lovaza TM 51 Curaxin 51 GP Pharm 51 Tanespimycin 51 SIR Spheres 51 Annexin V 51 candidate XP# 51 Junovan 51 investigational immunotherapy 51 ARG# 51 randomized controlled multicenter 51 miglustat 51 Debiopharm SA 51 Severe Sepsis 51 Minapharm 51 XIENCE V Stent System 51 romazarit 51 LEVADEX TM 51 Cinacalcet HCl 51 rhMBL 51 KeyNeurotek 51 Vitrasert R 51 Zentaris 51 initiate Phase IIb 51 Medtronic CoreValve 51 ACTEMRA TM 51 Zenvia Phase III 51 confirmatory pivotal 51 Cellerix 51 DiaPep# 51 sodium Injection 51 CIMZIA ™ 51 Quark Biotech 51 TREANDA 51 Terumo Heart 51 Glufosfamide 51 acute peripheral arterial 51 Biologics License Application 51 Trovax 51 ceftazidime 51 NTDDS 51 Igeneon 51 IND Investigational New 51 multicenter randomized placebo controlled 51 R lenalidomide 51 ARIKACE 51 Stemedica 51 ELADUR 51 Interventional Spine 51 Completes Patient Enrollment 51 Ceflatonin R 51 CYCLOSET ® 51 Asentar 51 Nasdaq PGNX today 51 Oncobionic 51 drug conjugate 51 Chronic Idiopathic Constipation 51 Zerenex 51 Arzerra TM 51 REVIVE Diabetes 51 Receives Orphan Drug 51 Grunenthal GmbH 51 Monoclonal antibody 51 Daclizumab